ClinicalTrials.gg
RecruitingNCT06545331Updated Oct 30, 2026

Study of XB010 in Subjects With Solid Tumors

A Phase 1 interventional study of XB010 and Pembrolizumab in Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer and Head and Neck Squamous Cell Cancer, sponsored by Exelixis. Recruiting at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Oct 30, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
396
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States — 43 open to participants now, 51 under way, 3 of them phase 3. Esophageal Squamous Cell Carcinoma · United States.

Planned enrollment
14th of 121
396 · median 61
Started
2024
with 8 others
Phase 1
44 of 139
15 open now
Primary completion
2026-11
later than 8 of 50 live
Registered
110th of 139
by date

Among the 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States, this one is the 14th largest by planned enrollment of the 121 interventional ones that give a count, is one of 9 that started in 2024, is one of 44 in phase 1, reaches primary completion later than 8 of the 50 other live ones, and was the 110th registered.

Esophageal Squamous Cell Carcinoma

679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

43 of the 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Esophageal Squamous Cell Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.

Read the detailed description

This study consists of Dose-Escalation and Cohort-Expansion Stages. The Dose-Escalation Stage is designed to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE[s]) of XB010 as a single agent, and to evaluate XB010 monotherapy RDE(s) in combination with pembrolizumab. The Cohort-Expansion Stage is designed to explore the clinical activity and further characterize the safety and tolerability of XB010 as monotherapy in multiple tumor-specific cohorts.

03

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors
  • Esophageal Squamous Cell Cancer
  • Head and Neck Squamous Cell Cancer
  • NSCLC (Non-small Cell Lung Cancer)
  • Hormone-receptor-positive Breast Cancer
  • Triple Negative Breast Cancer (TNBC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Age 18 years or older on the day of consent.
  • (ECOG) Performance Status of 0-1.
  • Adequate organ and marrow function.
  • Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, , or recurrent.

    • The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer).
  • Capable of understanding and complying with the protocol requirements and must have signed the document.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
396 participants (estimated)

Study arms

  • Experimental
    XB010 Single-Agent Dose Escalation Cohorts

    XB010 will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects

    Drug: XB010

  • Experimental
    XB010 + Pembrolizumab Dose Escalation Cohorts

    XB010+Pembrolizumab will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects

    Drug: XB010 · Drug: Pembrolizumab

  • Experimental
    XB010 Single-Agent Dose Expansion Cohorts

    XB010 will be administered at the recommended dose for expansion (RDE) every 3 weeks in the following tumor-specific cohorts: non-small cell lung cancer (NSCLC), hormone-receptor-positive breast cancer (HR+BC), head and neck squamous cell cancer (HNSCC), esophageal squamous cell cancer (ESCC), endometrial cancer (EC) and triple-negative breast cancer (TNBC)

    Drug: XB010

Interventions

  • DrugXB010

    IV administration of XB010

  • IV administration of Pembrolizumab

06

What researchers measure

Primary outcomes

  1. Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010

    To determine the MTD and/or RDE(s) for further evaluation of IV administration of XB010 alone and in combination therapy.

    Time frame: 18 months

  2. Dose-Escalation Stage: Safety of XB010

    To evaluate the safety of XB010 alone and in combination therapy through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs)

    Time frame: 18 months

  3. Dose-Escalation Stage: Duration of exposure of XB010 [Tolerability]

    To evaluate the tolerability of XB010 alone and in combination therapy through the evaluation of the duration of exposure of each component

    Time frame: 18 months

  4. Dose-Escalation Stage: Dose intensity of XB010 [Tolerability]

    To evaluate the tolerability of XB010 alone and in combination therapy through the evaluation of the dose intensity of each component

    Time frame: 18 months

  5. Cohort-Expansion Stage: Preliminary antitumor activity of XB010

    Objective Response Rate (ORR) as assessed by the Investigator per RECIST 1.1

    Time frame: 24 months

Secondary outcomes

  1. Dose-Escalation Stage: Maximum Plasma Concentration (Cmax) of XB010

    To evaluate the maximum plasma concentration of XB010 alone and in combination.

    Time frame: 18 Months

  2. Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax) of XB010

    To evaluate the time to maximum plasma concentration of XB010 alone and in combination.

    Time frame: 18 Months

  3. Dose-Escalation Stage: Clearance of XB010

    To evaluate the volume of plasma cleared of XB010 alone and in combination for a specified time period

    Time frame: 18 Months

  4. Dose-Escalation Stage: Area Under the Plasma Concentration Curve (AUC) of XB010

    To measure the Area Under the Plasma Concentration Curve of XB010 alone and in combination

    Time frame: 18 Months

  5. Dose-Escalation Stage: Minimum Plasma Concentration (Cmin) of XB010

    To evaluate the minimum plasma concentration of XB010 alone and in combination

    Time frame: 18 Months

  6. Dose-Escalation Stage: Immunogenicity of XB010

    To assess the immunogenicity of XB010 alone and in combination as measured by anti-drug antibody (ADA) analysis

    Time frame: 18 Months

  7. Cohort-Expansion Stage: Duration of exposure of XB010 [Tolerability]

    To evaluate the tolerability of XB010 through the evaluation of the duration of exposure

    Time frame: 24 Months

  8. Cohort-Expansion Stage: Dose intensity of XB010 [Tolerability]

    To evaluate the tolerability of XB010 through the evaluation of the dose intensity

    Time frame: 24 Months

  9. Cohort-Expansion Stage: Maximum Plasma Concentration (Cmax) of XB010

    To evaluate the maximum plasma concentration of XB010

    Time frame: 24 Months

  10. Cohort-Expansion Stage: Time to Maximum Plasma Concentration (Tmax) of XB010

    To evaluate the time to maximum plasma concentration of XB010

    Time frame: 24 Months

  11. Cohort-Expansion Stage: Clearance of XB010

    To evaluate the volume of plasma cleared of XB010 for a specified time period

    Time frame: 24 Months

  12. Cohort-Expansion Stage: Area Under the Plasma Concentration Curve (AUC) of XB010

    To measure the Area Under the Plasma Concentration Curve of XB010

    Time frame: 24 Months

  13. Cohort-Expansion Stage: Minimum Plasma Concentration (Cmin) of XB010

    To evaluate the minimum plasma concentration of XB010

    Time frame: 24 Months

  14. Cohort-Expansion Stage: Immunogenicity of XB010

    To assess the immunogenicity of XB010 as measured by anti-drug antibody (ADA) analysis

    Time frame: 24 Months

07

Study locations

18 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Nov 2026, 27 months after the start.

Of 42 phase 1 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 68. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2024
First posted
Aug 9, 2024
StartActual
Aug 6, 2024
Primary completionEst.
Nov 23, 2026
CompletionEst.
Oct 20, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now completed)
Show 2 sites
  • Georgetown University Medical Center · Washington D.C., United StatesRecruiting→Completed
  • Carolina BioOncology Institute · Huntersville, United StatesRecruiting→Completed
across 2 updates, Oct 15, 2026 – Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Carolina BioOncology Institute is now Completed
  2. Oct 15, 2026
    Georgetown University Medical Center is now Completed
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06545331
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Aug 6, 2024
Primary completion
Nov 23, 2026 (estimated)
Completion
Oct 20, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Exelixis Clinical Trials
Contact
druginfo@exelixis.com
1-888-EXELIXIS (888-393-5494)
Backup or International
Contact
650-837-7400
Study Director
study director · Exelixis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion